Risk Prediction and Right Ventricular Dilation in a Single-Institution Pulmonary Arterial Hypertension Cohort.
作者信息
Pi Hongyang, Carlson Selma D, Barros Lia M, Hogl Laurie, Kirkpatrick James N, Nolley Stephanie, Ralph David D, Rayner Samuel G, Leary Peter J
机构信息
Department of Medicine University of Washington Seattle WA.
Department of Medicine Veterans Administration Minneapolis Minneapolis MN.
出版信息
J Am Heart Assoc. 2022 Jul 19;11(14):e025521. doi: 10.1161/JAHA.122.025521. Epub 2022 Jul 13.
Abstract
摘要
相似文献
1
Risk Prediction and Right Ventricular Dilation in a Single-Institution Pulmonary Arterial Hypertension Cohort.
J Am Heart Assoc. 2022 Jul 19;11(14):e025521. doi: 10.1161/JAHA.122.025521. Epub 2022 Jul 13.
2
Right Ventricular Imaging for Predicting Risk in Pulmonary Arterial Hypertension: The Elephant in the Room.
Chest. 2023 May;163(5):1013-1015. doi: 10.1016/j.chest.2023.02.039.
3
CT signs of right ventricular dysfunction correlated with echocardiography-derived pulmonary arterial systolic pressure: incremental value of the pulmonary arterial diameter index.
Int J Cardiovasc Imaging. 2013 Dec;29 Suppl 2:109-18. doi: 10.1007/s10554-013-0322-7. Epub 2013 Nov 6.
4
Reply to: Correlation Between Right Ventricular Echocardiography Measurements and Functional Capacity in Patients With Pulmonary Arterial Hypertension.
Tex Heart Inst J. 2024 Jun 5;51(1). doi: 10.14503/THIJ-24-8451.
5
The importance of right ventricular remodelling in pulmonary arterial hypertension.
Heart. 2022 Aug 11;108(17):1338-1339. doi: 10.1136/heartjnl-2022-321143.
6
Imaging in pulmonary hypertension: Focus on the role of echocardiography.
Arch Cardiovasc Dis. 2014 Apr;107(4):261-71. doi: 10.1016/j.acvd.2014.02.005. Epub 2014 Apr 18.
7
New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med. 2022 Jul 1;206(1):12-13. doi: 10.1164/rccm.202204-0648ED.
8
Evaluation of right ventricular function in patients with pulmonary arterial hypertension by different right ventricular-pulmonary artery coupling methods.
Medicine (Baltimore). 2022 Sep 30;101(39):e30873. doi: 10.1097/MD.0000000000030873.
9
Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Ann Am Thorac Soc. 2017 May;14(5):682-689. doi: 10.1513/AnnalsATS.201608-655OC.
10
Echocardiographic assessment of right ventricular function: how to account for tricuspid regurgitation and pulmonary hypertension.
JACC Cardiovasc Imaging. 2012 Jul;5(7):747-53. doi: 10.1016/j.jcmg.2011.08.026.
引用本文的文献
1
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Chest. 2025 Jul;168(1):189-199. doi: 10.1016/j.chest.2024.12.029. Epub 2025 Jan 4.
2
Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension.
Circ Heart Fail. 2024 Nov;17(11):e012067. doi: 10.1161/CIRCHEARTFAILURE.124.012067. Epub 2024 Oct 22.
3
Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.
J Am Heart Assoc. 2024 Jul 2;13(13):e034151. doi: 10.1161/JAHA.123.034151. Epub 2024 Jun 21.
4
Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes.
Circ Res. 2023 Feb 3;132(3):254-266. doi: 10.1161/CIRCRESAHA.122.321923. Epub 2023 Jan 4.
本文引用的文献
1
Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.
PLoS One. 2020 Nov 11;15(11):e0241504. doi: 10.1371/journal.pone.0241504. eCollection 2020.
2
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.
Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
3
Risk assessment in pulmonary arterial hypertension.
Eur Respir J. 2018 Mar 29;51(3). doi: 10.1183/13993003.00279-2018. Print 2018 Mar.
4
The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP.
Zotero 插件